Aurora Cannabis Inc
NASDAQ:ACB
Intrinsic Value
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. [ Read More ]
The intrinsic value of one
ACB
stock under the Base Case scenario is
4.354
USD.
Compared to the current market price of 6.535 USD,
Aurora Cannabis Inc
is
Overvalued by 33%.
Aurora Cannabis Inc's market capitalization is 141.7m CAD.
ACB stock price is 6.535 USD.
ACB stock (4.354 USD) is 33% less than its price (6.535 USD).
ACB stock (3.419 USD) is 48% less than its price (6.535 USD). Open Relative Valuation
ACB has downside potential of 10% compared to the average analyst price target.
Open Wall St Estimates
ACB's Revenue has been falling by 2% per year for the last 3 years.
ACB's Revenue has grown by an exceptional 26% over the past 12 months.
ACB's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -14% to -24%, and is approaching profitability.
ACB's Revenue is forecast to grow at a rate of 28% per year over the next 3 years.
ACB's ROE (Return on Equity) has significantly increased in the last 3 years from -80% to -25%, and is approaching profitability.
ACB has negative Net Debt. This means that the company has more cash and short-term investments (149m CAD) than debt (78m CAD).
ACB has negative Operating Income for the last twelve months.
ACB has negative Net Income for the last twelve months.
ACB's ROE (Return on Equity) for the past 12 months is negative and is equal to -25%.
ACB's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -24%.
ACB has positive Gross Profit for the last twelve months.
ACB's long-term assets (817m CAD) exceed its long-term liabilties (301m CAD).
ACB has negative Free Cash Flow for the last twelve months.
ACB's D/E (Debt to Equity) is very low and is equal to 0.15.
ACB's short-term assets (407m CAD) exceed its short-term liabilties (107m CAD).
ACB has negative three-year average ROE (Return on Equity): -65%. The company is not efficient at transforming stockholders' equity into net income.
ACB has negative three-year average ROIC (Return on Invested Capital): -21%. The company is not efficient at using invested capital to generate operating income.
ACB's Altman Z-Score is very low and is equal to -10.44.
ACB doesn't generate enough operating income (-173m CAD) to safely cover interest payments on its debt (13m CAD).
Valuation Backtest
Aurora Cannabis Inc
Run backtest to discover the historical profit from buying and selling
ACB
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Aurora Cannabis Inc
Balance Sheet Decomposition
Aurora Cannabis Inc
| Current Assets | 406.5m |
| Cash & Short-Term Investments | 148.6m |
| Receivables | 43.3m |
| Other Current Assets | 214.7m |
| Non-Current Assets | 410.6m |
| PP&E | 295.6m |
| Intangibles | 79.1m |
| Other Non-Current Assets | 35.9m |
| Current Liabilities | 107.4m |
| Accounts Payable | 22.7m |
| Accrued Liabilities | 38.6m |
| Other Current Liabilities | 46.1m |
| Non-Current Liabilities | 193.3m |
| Long-Term Debt | 78.4m |
| Other Non-Current Liabilities | 115m |
Earnings Waterfall
Aurora Cannabis Inc
|
Revenue
|
267m
CAD
|
|
Cost of Revenue
|
-261.8m
CAD
|
|
Gross Profit
|
5.2m
CAD
|
|
Operating Expenses
|
-178.6m
CAD
|
|
Operating Income
|
-173.5m
CAD
|
|
Other Expenses
|
39.5m
CAD
|
|
Net Income
|
-133.9m
CAD
|
Free Cash Flow Analysis
Aurora Cannabis Inc
What is Free Cash Flow?
ACB Profitability Score
Profitability Due Diligence
Aurora Cannabis Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Aurora Cannabis Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
ACB Solvency Score
Solvency Due Diligence
Aurora Cannabis Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Score
Aurora Cannabis Inc's solvency score is 48/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACB Price Targets Summary
Aurora Cannabis Inc
According to Wall Street analysts, the average 1-year price target for
ACB
is 5.909 USD
with a low forecast of 3.701 USD and a high forecast of 9.716 USD.
Shareholder Return
ACB Price
Aurora Cannabis Inc
| Average Annual Return | -65.63% |
| Standard Deviation of Annual Returns | 19.88% |
| Max Drawdown | -100% |
| Market Capitalization | 141.7m CAD |
| Shares Outstanding | 15 726 900 |
| Percentage of Shares Shorted | 3.1% |
ACB News
Last Important Events
Aurora Cannabis Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Aurora Cannabis Inc
Company Profile
Aurora Cannabis Inc
Country
Industry
Market Cap
Dividend Yield
Description
Aurora Cannabis, Inc. engages in the production, distribution and sale of cannabis products. The firm's principal business lines are focused on the production, distribution and sale of cannabis and cannabis related products in Canada and internationally. The firm's portfolio of brands includes Aurora, Aurora Drift, San Rafael '71, Daily Special, MedReleaf, CanniMed, Whistler, Reliva and KG7 CBD. Its cannabis products are primarily cultivated and manufactured in the facilities in Edmonton, Alberta; Bradford Ontario; Pemberton, British Columbia; and Odense, Denmark. The firm is focused on offering its cannabis products to global medical cannabis market, recreational cannabis market and global hemp-derived cannabidiol (CBD) markets. The company produces approximately 150,000 kilograms (kg) of cannabis biomass annually. Its subsidiaries include 1769474 Alberta Ltd., 2105657 Alberta Inc., Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Aurora Nordic Cannabis A/S, and Reliva, LLC, among others.
Contact
IPO
Employees
Officers
The intrinsic value of one
ACB
stock under the Base Case scenario is
4.354
USD.
Compared to the current market price of 6.535 USD,
Aurora Cannabis Inc
is
Overvalued by 33%.
You don't have any saved screeners yet
